Indian stocks: Visit www.stage2stocks.com →

Oric Pharmaceuticals, Inc.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Oric Pharmaceuticals is in Stage 2, the uptrend phase, now in week 10 (since Aug 14, 2026). It closed at $13.63, 7.0% below its 52-week high and above its 200-day average, which is rising.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. More about the company

$13.63
-2.43% today
$1.4B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ORIC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 19w
S4 16w
S4 14w
S2 22w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 7w → S3 10w → S2 19w → S3 7w → S4 6w → S1 11w → S4 16w → S1 1w → S2 2w → S1 1w → S4 14w → S1 5w → S2 22w → S3 7w → S4 3w → S1 1w → S2 6w → S3 3w → S4 10w → S1 4w → S2 10w current
Total tracked: 166 weeks across 21 stage runs.

ORIC among Biotechnology157th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…157ORICStage 2 · wk 1061+2.3%
vs 52W High
-7.0%
$7.48 lo$14.65 hi
7.0% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
22.4%
200 DMA: $11.13 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.85x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+2.3%
3M
+12.6%
6M
+30.7%
YTD
+66.8%
1Y
+8.2%
Scan Membership
Breakout Watch
Latest: 2025-02-04
5 appearances in last 60 days. First seen: 2021-02-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 10 · Vol 0.85x
2026-10-21S2
Wk 10 · Vol 1.01x
2026-10-20S2
Wk 10 · Vol 1.51x
2026-10-19S2
Wk 10 · Vol 0.88x
2026-10-16S2
Wk 9 · Vol 0.71x
2026-10-15S2
Wk 9 · Vol 1.15x
2026-10-14S2
Wk 9 · Vol 1.26x
2026-10-13S2
Wk 9 · Vol 0.80x
2026-10-12S2
Wk 9 · Vol 0.61x
2026-10-09S2
Wk 8 · Vol 0.74x
2026-10-08S2
Wk 8 · Vol 1.86x
2026-10-07S2
Wk 8 · Vol 0.54x
Moving averages & range
50 DMA
$12.96
200 DMA
$11.13
52W High
$14.65
52W Low
$7.48
5D Low
$12.35
Resistance levels (recent highs)
20d High
$13.97
60d High
$14.65
120d High
$14.65
250d High
$14.65
Next resistance
+2.5%
to 20d High
ROE
-39.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.7

Oric Pharmaceuticals: quick answers

What stage is Oric Pharmaceuticals in?

As of Oct 22, 2026, Oric Pharmaceuticals (ORIC) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 14, 2026 and is in week 10. What the four stages mean

Is Oric Pharmaceuticals in an uptrend?

Yes. Oric Pharmaceuticals is in a Stage 2 uptrend. It trades 22.4% above its 200-day average, which is rising.

How far is Oric Pharmaceuticals from its 52-week high?

Oric Pharmaceuticals closed at $13.63 on Oct 22, 2026, 7.0% below its 52-week high of $14.65. Its 52-week low is $7.48.

How has Oric Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Oric Pharmaceuticals is up 8.2% over the past year and up 66.8% so far in 2026.

Which sector and industry is Oric Pharmaceuticals in?

Oric Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.